Drug combination found to extend lifespan by 30 per cent
A combination of two cancer drugs significantly boosts lifespan in mice, according to a new study that may lead to better strategies for longevity.
The drugs rapamycin and trametinib given together as a combination can increase mice lifespan by up to 30 per cent, say researchers, including from the Max Planck Institute for Biology of Ageing.
Trametinib alone can extend lifespan by 5 to 10 per cent and rapamycin by 15–20 per cent, according to the study published in the journal Nature Ageing.
Researchers say the drug combination has several other positive effects on mice health in old age, including less chronic inflammation in tissues and a delayed onset of cancer.
Previous studies showed potent anti-ageing effects of rapamycin in several animals. Trametinib wasn't known to extend lifespan in mice but previous research in flies indicated it might.
In humans, the two drugs have been used for cancer treatment.
While both drugs act on the same chemical network in the body, their combination appears to achieve novel effects that are likely not attributable to just an increase in dosage.
Gene activity analysis of mice tissues shows the combination influences genes differently than is achieved by administering the drugs individually. The analysis reveals specific gene activity changes that are only caused by the combination of the two drugs.
In further studies, researchers hope to determine the optimal dose and route of administration of trametinib to maximise its life-prolonging effects while minimising unwanted side effects.
'Trametinib, especially in combination with rapamycin, is a good candidate to be tested in clinical trials as a geroprotector,' Sebastian Grönke, a co-author of the study, says.
'We hope that our results will be taken up by others and tested in humans. Our focus is on optimising the use of trametinib in animal models.'
While the exact same kind of effect may not be possible in humans, researchers hope the drugs can help people stay healthy and disease-free for longer in life.
"Further research in humans in years to come will help us to elucidate how these drugs may be useful to people and who might be able to benefit,' British geneticist Dame Linda Partridge said in a statement.
Scientists hope the drug combination may be developed into a promising strategy for combating age-related diseases and promoting longevity.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
8 hours ago
- The Independent
Revealed: The AI chatbot requests that cause the most carbon emissions
A new study reveals that every query to large language models like ChatGPT consumes energy and generates carbon emissions. Complex reasoning questions, such as those in abstract algebra or philosophy, lead to significantly higher carbon emissions, up to six times more than simpler queries. Models designed for explicit reasoning processes produce substantially more carbon dioxide, with some generating up to 50 times more emissions than concise response models. The study highlights an "accuracy-sustainability trade-off," where highly accurate AI models often result in greater energy consumption and carbon footprint. Researchers recommend that users reduce emissions by prompting AI for concise answers and reserving high-capacity models for tasks that genuinely require their advanced capabilities.
The Independent
8 hours ago
- The Independent
The simple test that could predict how long you will live
A new study published in the European Journal of Preventive Cardiology explored whether a simple sitting-rising test could predict premature deaths. Researchers tested 4,282 adults aged 46-75 in Rio de Janeiro, Brazil, from 1998 to 2023, to evaluate non-aerobic physical fitness, including muscle strength, flexibility, and balance. The test required participants to sit and rise from the floor without using support from hands, elbows, or knees, with points deducted for any assistance or loss of balance. The study concluded that non-aerobic physical fitness, as assessed by this test, was a significant predictor of natural and cardiovascular mortality. After about 12 years, participants with a perfect 10 score had a 3.7 per cent death rate, while those scoring 0-4 points showed a dramatically higher death rate of 42.1 per cent.
The Independent
9 hours ago
- The Independent
A simple blood test could offer first reliable diagnosis for ME
A simple blood test could provide the first reliable diagnosis for myalgic encephalomyelitis (ME) and end the lengthy process of trying to identify the debilitating condition, scientists have found. It's thought more than 400,000 people in the UK suffer with the condition, also known as chronic fatigue syndrome (CFS). Pain, brain fog and extreme low energy that does not improve with sleep are just some of the symptoms of ME. There is no cure and the cause is unknown. Currently the only way to diagnose it is by ruling out other illnesses – a long process that can mean patients wait years for a diagnosis. However, researchers at the University of Edinburgh believe they have made a breakthrough. The study published in the Journal EMBO Molecular Medicine used data from the UK Biobank – a large-scale resource based on the health data and biological samples of 500,000 UK participants. Researchers compared blood samples from 1,455 ME patients with more than 131,000 healthy people. They identified differences in cell counts and molecules that differed in concentrations between the two. The differences in samples for the ME patients were related to chronic inflammation, insulin resistance and liver dysfunction. These findings were compared and replicated in data from a group of American patients and healthy controls. Researchers found 116 'biomarkers' for ME in the blood of men and women with the condition. This is a key finding because the condition affects men and women differently. Professor Chris Ponting, of the university's Institute of Genetics and Cancer, said: 'For so long people with ME/CFS have been told it's all in their head. It's not. We see [it] in their blood. 'Evidence of a large number of replicated and diverse blood biomarkers that differentiate between ME/CFS cases and controls should dispel any lingering perception it is caused by deconditioning and exercise intolerance.' These biomarkers did not change when the participants were any more active – consistent with the view graded exercise therapy, which aims to gradually increase activity levels, is unlikely to be helpful. In fact, the largest differences were seen in people who reported post-exertional malaise. This is when the symptoms of the condition become worse even after minor physical effort. Dr Sjoerd Beentjes, of the university's School of Mathematics, said: 'Blood differences are sometimes attributed to reduced activity levels rather than ME/CFS directly. Our study provides strong evidence ME/CFS affects blood traits through paths other than activity.' However, this research is still at an early stage and there is no guarantee a test will be possible, study authors stressed. Professor Kevin McConway, Emeritus Professor of Applied Statistics, Open University, who was not part of the study, said: 'There is a lot more to do.' 'These findings could help in finding a set of blood biomarkers that can reasonably reliably distinguish people with ME/CFS from those who do not have that condition, but that, without a lot of further work, the findings do not in themselves provide such a set of biomarkers,' he added.
